Diabetic Retinopathy
📧 Sign up to get email alerts when something new happens for Diabetic Retinopathy.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-04-24EMA Authorised: Ranluspec (ranibizumab) — Lupin Europe GmbH
EMA authorised Ranluspec (ranibizumab) from Lupin Europe GmbH. The product is indicated for several retinal conditions including wet age-rel…
-
EMA approval · 2026-02-26EMA Authorised: Yesafili (aflibercept) — Biosimilar Collaborations Ireland Limited
Yesafili is an authorised aflibercept biosimilar by Biosimilar Collaborations Ireland Limited for various retinal diseases, expanding treatm…
-
EMA approval · 2026-02-25EMA Authorised: Byooviz (ranibizumab) — Samsung Bioepis NL B.V.
EMA authorised Byooviz (ranibizumab) from Samsung Bioepis NL B.V. for multiple retinal diseases, including wet age-related macular degenerat…
-
EMA approval · 2025-12-17EMA Authorised: Lucentis (ranibizumab) — Novartis Europharm Limited
EMA authorised Lucentis (ranibizumab) for multiple ophthalmic indications including wet age-related macular degeneration, macular edema, dia…
-
EMA approval · 2025-12-10EMA Authorised: Eydenzelt (aflibercept) — Celltrion Healthcare Hungary Kft.
EMA authorised Eydenzelt (aflibercept) from Celltrion Healthcare Hungary Kft. for multiple ocular conditions including wet age-related macul…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2025-11-21EMA Authorised: Eiyzey (aflibercept) — Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.
The EMA authorised Eiyzey (aflibercept) from Zaklady Farmaceutyczne Polpharma S.A. for multiple retinal diseases, including wet age-related …
-
EMA approval · 2025-11-14EMA Authorised: Ranivisio (ranibizumab) — Midas Pharma GmbH
The EMA authorised Ranivisio (ranibizumab) for ocular indications including wet age-related macular degeneration, macular edema, and diabeti…
-
EMA approval · 2025-11-07EMA Authorised: Ahzantive (aflibercept) — Formycon AG
EMA authorised Ahzantive (aflibercept) from Formycon AG for several retinal diseases including wet age-related macular degeneration and diab…
-
FDA approval · 2025-08-15FDA Approved: BYOOVIZ — Supplemental Application (BIOGEN INC.)
FDA approved a supplemental application for BYOOVIZ (ranibizumab-nuna) from Biogen, updating its labeling with additional indications for oc…
-
EMA approval · 2024-03-26EMA Authorised: Ximluci (ranibizumab) — STADA Arzneimittel AG
European Medicines Agency authorised Ximluci (ranibizumab) for indications including wet age-related macular degeneration, macular edema, an…
-
FDA approval · 2023-10-03FDA Approved: BYOOVIZ — Supplemental Application (BIOGEN INC.)
FDA approved Biogen's BYOOVIZ (ranibizumab-nuna) via a supplemental application, providing an additional approval for this ranibizumab biosi…